By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gen-Probe and DiagnoCure said today that Gen-Probe has received a regulatory medical device license from Health Canada, the Canadian government's department responsible for national public health, for a molecular urine test that determines the need for repeat biopsies for prostate cancer.

Gen-Probe exclusively licensed the worldwide rights to the PCA3 gene, on which its Progensa PCA3 assay is based, from its commercial partner DiagnoCure in 2003.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.